Trial Outcomes & Findings for Novel Methods for Ascertainment of Gout Flares -A Pilot Study (NCT NCT02855437)

NCT ID: NCT02855437

Last Updated: 2019-10-28

Results Overview

Percentage of total study population preferring IVR vs. RheumPRO

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

44 participants

Primary outcome timeframe

6 months

Results posted on

2019-10-28

Participant Flow

The target population recruited was patients with gout. Patients were recruited from the UAB gout clinic, The Kirklin Clinic, and the UNMC gout clinic.

Participant milestones

Participant milestones
Measure
Interactive Voice Response, Then RheumPRO
IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
RheumPro Smartphone Application, Then IVR
RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled "pop-up" to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more "pop-ups" at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm.
Phase 1
STARTED
23
21
Phase 1
COMPLETED
21
19
Phase 1
NOT COMPLETED
2
2
Crossover Period (Same Day)
STARTED
21
19
Crossover Period (Same Day)
COMPLETED
21
19
Crossover Period (Same Day)
NOT COMPLETED
0
0
Phase 2
STARTED
21
19
Phase 2
COMPLETED
20
18
Phase 2
NOT COMPLETED
1
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Novel Methods for Ascertainment of Gout Flares -A Pilot Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Overall
n=44 Participants
Overall description of participants in the pilot study entitled, "Novel Methods for Ascertainment of Gout Flares -A Pilot Study"
Age, Continuous
49.3 years
STANDARD_DEVIATION 14.5 • n=99 Participants
Sex: Female, Male
Female
7 Participants
n=99 Participants
Sex: Female, Male
Male
37 Participants
n=99 Participants
Race/Ethnicity, Customized
Race · White race
30 Participants
n=99 Participants
Race/Ethnicity, Customized
Race · Black or other race
14 Participants
n=99 Participants
Age of first gout flare
38.3 Years
STANDARD_DEVIATION 18.6 • n=99 Participants
Number of flares prior 6 months
2-3 flares in prior 6 months
19 Participants
n=99 Participants
Number of flares prior 6 months
>=4 flares in prior 6 months
25 Participants
n=99 Participants

PRIMARY outcome

Timeframe: 6 months

Population: Preference of IVR and StudyBuddy for reporting gout flares as reported by participants

Percentage of total study population preferring IVR vs. RheumPRO

Outcome measures

Outcome measures
Measure
Interactive Voice Response
n=38 Participants
The interactive voice response system (IVR) is an automated telephone system that is used to contact participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed. IVR (Phone call): IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack
RheumPro Smartphone Application
n=38 Participants
RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed. RheumPro (Smartphone application): RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled "pop-up" to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more "pop-ups" at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. In addition RheumPro questionnaires at months 1 , 3, and 6 will assess RheumPro ease of use.
Preference IVR vs RheumPRO
3 Participants
28 Participants

PRIMARY outcome

Timeframe: 6 months

Feasibility ----Assessed by the percentage of participants completing answer IRV/RheumPRO queries.

Outcome measures

Outcome measures
Measure
Interactive Voice Response
n=38 Participants
The interactive voice response system (IVR) is an automated telephone system that is used to contact participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed. IVR (Phone call): IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack
RheumPro Smartphone Application
n=38 Participants
RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed. RheumPro (Smartphone application): RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled "pop-up" to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more "pop-ups" at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. In addition RheumPro questionnaires at months 1 , 3, and 6 will assess RheumPro ease of use.
Feasibility of Using IVR vs. RheumPRO to Report Gout Flares
81 percentage of weekly response
Standard Deviation 21
80 percentage of weekly response
Standard Deviation 25

Adverse Events

Interactive Voice Response

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

RheumPro Smartphone Application

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jeff Foster

UNIVERSITY OF ALABAMA AT BIRMINGHAM

Phone: 205-996-6086

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place